PKG inhibits TCF signaling in colon cancer cells by blocking Β-catenin expression and activating FOXO4

I. K. Kwon, R. Wang, Muthusamy Thangaraju, Shuang Huang, Kebin Liu, R. Dashwood, N. Dulin, V. Ganapathy, Darren D Browning

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Activation of cGMP-dependent protein kinase (PKG) has anti-tumor effects in colon cancer cells but the mechanisms are not fully understood. This study has examined the regulation of Β-catenin/TCF signaling, as this pathway has been highlighted as central to the anti-tumor effects of PKG. We show that PKG activation in SW620 cells results in reduced Β-catenin expression and a dramatic inhibition of TCF-dependent transcription. PKG did not affect protein stability, nor did it increase phosphorylation of the amino-terminal Ser33/37/Thr41 residues that are known to target Β-catenin for degradation. However, we found that PKG potently inhibited transcription from a luciferase reporter driven by the human CTNNB1 promoter, and this corresponded to reduced Β-catenin mRNA levels. Although PKG was able to inhibit transcription from both the CTNNB1 and TCF reporters, the effect on protein levels was less consistent. Ectopic PKG had a marginal effect on Β-catenin protein levels in SW480 and HCT116 but was able to inhibit TCF-reporter activity by over 80%. Investigation of alternative mechanisms revealed that cJun-N-terminal kinase (JNK) activation was required for the PKG-dependent regulation of TCF activity. PKG activation caused Β-catenin to bind to FOXO4 in colon cancer cells, and this required JNK. Activation of PKG was also found to increase the nuclear content of FOXO4 and increase the expression of the FOXO target genes MnSOD and catalase. FOXO4 activation was required for the inhibition of TCF activity as FOXO4-specific short-interfering RNA completely blocked the inhibitory effect of PKG. These data illustrate a dual-inhibitory effect of PKG on TCF activity in colon cancer cells that involves reduced expression of Β-catenin at the transcriptional level, and also Β-catenin sequestration by FOXO4 activation.

Original languageEnglish (US)
Pages (from-to)3423-3434
Number of pages12
JournalOncogene
Volume29
Issue number23
DOIs
StatePublished - Jun 10 2010

Fingerprint

Catenins
Colonic Neoplasms
MAP Kinase Kinase 4
Cyclic GMP-Dependent Protein Kinases
Protein Stability
Luciferases
Catalase
Small Interfering RNA
Neoplasms
Phosphorylation
Messenger RNA

Keywords

  • B-catenin
  • CGMP
  • Colon cancer
  • FOXO
  • PKG
  • TCF

ASJC Scopus subject areas

  • Molecular Biology
  • Cancer Research
  • Genetics

Cite this

PKG inhibits TCF signaling in colon cancer cells by blocking Β-catenin expression and activating FOXO4. / Kwon, I. K.; Wang, R.; Thangaraju, Muthusamy; Huang, Shuang; Liu, Kebin; Dashwood, R.; Dulin, N.; Ganapathy, V.; Browning, Darren D.

In: Oncogene, Vol. 29, No. 23, 10.06.2010, p. 3423-3434.

Research output: Contribution to journalArticle

Kwon, I. K. ; Wang, R. ; Thangaraju, Muthusamy ; Huang, Shuang ; Liu, Kebin ; Dashwood, R. ; Dulin, N. ; Ganapathy, V. ; Browning, Darren D. / PKG inhibits TCF signaling in colon cancer cells by blocking Β-catenin expression and activating FOXO4. In: Oncogene. 2010 ; Vol. 29, No. 23. pp. 3423-3434.
@article{9aa4ec16a10049ed845b599a2d0fd2ee,
title = "PKG inhibits TCF signaling in colon cancer cells by blocking Β-catenin expression and activating FOXO4",
abstract = "Activation of cGMP-dependent protein kinase (PKG) has anti-tumor effects in colon cancer cells but the mechanisms are not fully understood. This study has examined the regulation of Β-catenin/TCF signaling, as this pathway has been highlighted as central to the anti-tumor effects of PKG. We show that PKG activation in SW620 cells results in reduced Β-catenin expression and a dramatic inhibition of TCF-dependent transcription. PKG did not affect protein stability, nor did it increase phosphorylation of the amino-terminal Ser33/37/Thr41 residues that are known to target Β-catenin for degradation. However, we found that PKG potently inhibited transcription from a luciferase reporter driven by the human CTNNB1 promoter, and this corresponded to reduced Β-catenin mRNA levels. Although PKG was able to inhibit transcription from both the CTNNB1 and TCF reporters, the effect on protein levels was less consistent. Ectopic PKG had a marginal effect on Β-catenin protein levels in SW480 and HCT116 but was able to inhibit TCF-reporter activity by over 80{\%}. Investigation of alternative mechanisms revealed that cJun-N-terminal kinase (JNK) activation was required for the PKG-dependent regulation of TCF activity. PKG activation caused Β-catenin to bind to FOXO4 in colon cancer cells, and this required JNK. Activation of PKG was also found to increase the nuclear content of FOXO4 and increase the expression of the FOXO target genes MnSOD and catalase. FOXO4 activation was required for the inhibition of TCF activity as FOXO4-specific short-interfering RNA completely blocked the inhibitory effect of PKG. These data illustrate a dual-inhibitory effect of PKG on TCF activity in colon cancer cells that involves reduced expression of Β-catenin at the transcriptional level, and also Β-catenin sequestration by FOXO4 activation.",
keywords = "B-catenin, CGMP, Colon cancer, FOXO, PKG, TCF",
author = "Kwon, {I. K.} and R. Wang and Muthusamy Thangaraju and Shuang Huang and Kebin Liu and R. Dashwood and N. Dulin and V. Ganapathy and Browning, {Darren D}",
year = "2010",
month = "6",
day = "10",
doi = "10.1038/onc.2010.91",
language = "English (US)",
volume = "29",
pages = "3423--3434",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "23",

}

TY - JOUR

T1 - PKG inhibits TCF signaling in colon cancer cells by blocking Β-catenin expression and activating FOXO4

AU - Kwon, I. K.

AU - Wang, R.

AU - Thangaraju, Muthusamy

AU - Huang, Shuang

AU - Liu, Kebin

AU - Dashwood, R.

AU - Dulin, N.

AU - Ganapathy, V.

AU - Browning, Darren D

PY - 2010/6/10

Y1 - 2010/6/10

N2 - Activation of cGMP-dependent protein kinase (PKG) has anti-tumor effects in colon cancer cells but the mechanisms are not fully understood. This study has examined the regulation of Β-catenin/TCF signaling, as this pathway has been highlighted as central to the anti-tumor effects of PKG. We show that PKG activation in SW620 cells results in reduced Β-catenin expression and a dramatic inhibition of TCF-dependent transcription. PKG did not affect protein stability, nor did it increase phosphorylation of the amino-terminal Ser33/37/Thr41 residues that are known to target Β-catenin for degradation. However, we found that PKG potently inhibited transcription from a luciferase reporter driven by the human CTNNB1 promoter, and this corresponded to reduced Β-catenin mRNA levels. Although PKG was able to inhibit transcription from both the CTNNB1 and TCF reporters, the effect on protein levels was less consistent. Ectopic PKG had a marginal effect on Β-catenin protein levels in SW480 and HCT116 but was able to inhibit TCF-reporter activity by over 80%. Investigation of alternative mechanisms revealed that cJun-N-terminal kinase (JNK) activation was required for the PKG-dependent regulation of TCF activity. PKG activation caused Β-catenin to bind to FOXO4 in colon cancer cells, and this required JNK. Activation of PKG was also found to increase the nuclear content of FOXO4 and increase the expression of the FOXO target genes MnSOD and catalase. FOXO4 activation was required for the inhibition of TCF activity as FOXO4-specific short-interfering RNA completely blocked the inhibitory effect of PKG. These data illustrate a dual-inhibitory effect of PKG on TCF activity in colon cancer cells that involves reduced expression of Β-catenin at the transcriptional level, and also Β-catenin sequestration by FOXO4 activation.

AB - Activation of cGMP-dependent protein kinase (PKG) has anti-tumor effects in colon cancer cells but the mechanisms are not fully understood. This study has examined the regulation of Β-catenin/TCF signaling, as this pathway has been highlighted as central to the anti-tumor effects of PKG. We show that PKG activation in SW620 cells results in reduced Β-catenin expression and a dramatic inhibition of TCF-dependent transcription. PKG did not affect protein stability, nor did it increase phosphorylation of the amino-terminal Ser33/37/Thr41 residues that are known to target Β-catenin for degradation. However, we found that PKG potently inhibited transcription from a luciferase reporter driven by the human CTNNB1 promoter, and this corresponded to reduced Β-catenin mRNA levels. Although PKG was able to inhibit transcription from both the CTNNB1 and TCF reporters, the effect on protein levels was less consistent. Ectopic PKG had a marginal effect on Β-catenin protein levels in SW480 and HCT116 but was able to inhibit TCF-reporter activity by over 80%. Investigation of alternative mechanisms revealed that cJun-N-terminal kinase (JNK) activation was required for the PKG-dependent regulation of TCF activity. PKG activation caused Β-catenin to bind to FOXO4 in colon cancer cells, and this required JNK. Activation of PKG was also found to increase the nuclear content of FOXO4 and increase the expression of the FOXO target genes MnSOD and catalase. FOXO4 activation was required for the inhibition of TCF activity as FOXO4-specific short-interfering RNA completely blocked the inhibitory effect of PKG. These data illustrate a dual-inhibitory effect of PKG on TCF activity in colon cancer cells that involves reduced expression of Β-catenin at the transcriptional level, and also Β-catenin sequestration by FOXO4 activation.

KW - B-catenin

KW - CGMP

KW - Colon cancer

KW - FOXO

KW - PKG

KW - TCF

UR - http://www.scopus.com/inward/record.url?scp=77953480176&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953480176&partnerID=8YFLogxK

U2 - 10.1038/onc.2010.91

DO - 10.1038/onc.2010.91

M3 - Article

VL - 29

SP - 3423

EP - 3434

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 23

ER -